Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics.
Through its Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com.
Pro Med Diagnostics is a Medical Diagnostic company specialising in the supply of laboratory based diagnostic products in the field of Fungal and Infectious diseases.
The founders of Pro Med Diagnostics, Neil and Anne Barker, have worked within the Medical Diagnostic field for all of their professional careers bringing a wealth of knowledge and experience to the organisation. Pro Med Diagnostics focuses on delivering an optimal level of customer support from the supply of quality products and service delivery.
Roivant to announce Q3 2026 financial results
Blacksmith Medicines granted European patent for LpxC-targeting antibacterial compounds
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays